BiotechTube

AFQ056 + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease, Chorea

Trial Timeline

Nov 1, 2009 → —

NCT ID
NCT01019473

About AFQ056 + Placebo

AFQ056 + Placebo is a phase 2 stage product being developed by Novartis for Huntington's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01019473. Target conditions include Huntington's Disease, Chorea.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (11)

NCT IDPhaseStatus
NCT04771143Phase 1Withdrawn
NCT03242928Phase 2Completed
NCT02920892Phase 2Completed
NCT01813019Phase 2Terminated
NCT01491529Phase 2Completed
NCT01385592Phase 2Completed
NCT01357239Phase 2Completed
NCT01253629Phase 2Completed
NCT01019473Phase 2Terminated
NCT00888004Phase 2Completed
NCT00582673Phase 2Completed

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
RO7234292 (RG6042)RochePhase 2
52
RG6496 + PlaceboRochePhase 1
33
PF-02545920 + PF-02545920PfizerPhase 2
51
20 mg BID of PF-02545920PfizerPhase 2
51
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
51
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
30
TetrabenazineLundbeckApproved
82
BN82451B + PlaceboIpsenPhase 2
49
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
38
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
36
WVE-120101 + PlaceboWaVe Life SciencesPhase 1/2
36
SAGE-718Supernus PharmaceuticalsPhase 3
72
SAGE-718 + PlaceboSupernus PharmaceuticalsPhase 2
47
OMS643762 + PlaceboOmeros CorporationPhase 2
47
VX15/2503 + PlaceboVaccinexPhase 2
44

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85